UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 361

Sortiert nach

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.155-163

2009

Link zum Volltext

Verfügbarkeit prüfen

Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

Clinical pharmacology and therapeutics, 2008-12, Vol.84 (6), p.704-709

2008

Link zum Volltext

Verfügbarkeit prüfen

Kinase Inhibitors: The Reality Behind the Success

Clinical pharmacology and therapeutics, 2017-11, Vol.102 (5), p.726-730

2017

Link zum Volltext

Verfügbarkeit prüfen

The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321

Cancer chemotherapy and pharmacology, 2022-04, Vol.89 (4), p.551-557

2022

Link zum Volltext

Verfügbarkeit prüfen

E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia

Leukemia, 2017-02, Vol.31 (2), p.502-505

2017

Link zum Volltext

Verfügbarkeit prüfen

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

Clinical pharmacology and therapeutics, 2016-06, Vol.99 (6), p.651-660

2016

Link zum Volltext

Verfügbarkeit prüfen

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9139-9143

2004

Link zum Volltext

Verfügbarkeit prüfen

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

Clinical cancer research, 2003-08, Vol.9 (9), p.3246-3253

2003

Link zum Volltext

Verfügbarkeit prüfen

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Considerations for New Targeted Therapies

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.208-211

2009

Link zum Volltext

Verfügbarkeit prüfen

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity

Clinical and translational science, 2017-09, Vol.10 (5), p.412-420

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies

Journal of clinical oncology, 2005-06, Vol.23 (17), p.3906-3911

2005

Link zum Volltext

Verfügbarkeit prüfen

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

Clinical and translational science, 2017-07, Vol.10 (4), p.271-279

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan

Clinical cancer research, 2005-11, Vol.11 (21), p.7800-7806

2005

Link zum Volltext

Verfügbarkeit prüfen

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

Molecular cancer therapeutics, 2002-05, Vol.1 (7), p.545

2002

Link zum Volltext

Verfügbarkeit prüfen

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

Clinical pharmacology and therapeutics, 2011-05, Vol.89 (5), p.693-701

2011

Link zum Volltext

Verfügbarkeit prüfen

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.642-650

2012

Link zum Volltext

Verfügbarkeit prüfen

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

Clinical cancer research, 2004-12, Vol.10 (24), p.8341-8350

2004

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies

Clinical cancer research, 2001-08, Vol.7 (8), p.2292-2300

2001

Link zum Volltext

Verfügbarkeit prüfen

ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression

Clinical and translational science, 2016-02, Vol.9 (1), p.51-59

2016

Link zum Volltext

Verfügbarkeit prüfen

Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly

Journal of clinical oncology, 2005-02, Vol.23 (6), p.1070-1077

2005

Link zum Volltext

Verfügbarkeit prüfen

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

Investigational new drugs, 2006-07, Vol.24 (4), p.291-297

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Journal of clinical oncology, 2006-02, Vol.24 (4), p.552-562

2006

Link zum Volltext

Verfügbarkeit prüfen

Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel

Clinical cancer research, 2001-10, Vol.7 (10), p.3229-3238

2001

Link zum Volltext

Verfügbarkeit prüfen

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Clinical cancer research, 2004-03, Vol.10 (6), p.1976-1983

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 361

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(336)
Mit Volltextzugriff
(311)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(345)
Life Sciences & Biomedicine
(284)
Humans
(173)
Biological And Medical Sciences
(146)
Female
(126)
Male
(125)
Medical Sciences
(116)
Animals
(91)
Adult
(83)
Middle Aged
(73)
Pharmacology. Drug Treatments
(72)
Oncology
(66)
Physical Sciences
(64)
Aged
(61)
Antineoplastic Agents
(43)
Pharmacology & Pharmacy
(38)
Neoplasms - Drug Therapy
(37)
Chemotherapy
(36)
Fundamental And Applied Biological Sciences. Psychology
(36)
Chemistry
(28)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

Kinase Inhibitors: The Reality Behind the Success

The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321

E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

Pharmacokinetic Considerations for New Targeted Therapies

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity

Pharmacokinetics of 5-Azacitidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies

ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression

Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel

Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel

Suchergebnisse filtern